

The information contained in this announcement is not a prospectus and does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of any securities of Jamjoom Pharmaceuticals Factory Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction, including in or into the United States, Canada, the United Kingdom, Japan, Australia or South Africa.

Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Any offer to acquire shares pursuant to the proposed Offering (as defined below) will be made, and any investor should make his investment decision solely on the basis of the information that is contained in the formal offering documents to be published by Jamjoom Pharmaceuticals Factory Company in due course in connection with the listing and trading of its ordinary shares on the Main Market of the Saudi Exchange.

Copies of this announcement are not being made and may not be distributed or sent, directly or indirectly, into the United States of America (including its territories and possessions, any State of the United States and the District of Columbia), Canada, the United Kingdom, Japan, Australia or any other jurisdiction in which offers or sales would be prohibited by applicable law.

Press Release

Jamjoom Pharmaceuticals Factory Company Announces Results of The Subscription Period for Individual Investors

JEDDAH – 06 June 2023 – Jamjoom Pharmaceuticals Factory Company (*“Jamjoom Pharma”* or the *“Company”* or the *“Issuer”*), a leading pharmaceutical manufacturer and marketer in the Kingdom of Saudi Arabia (*“KSA”* or the *“Kingdom”*) and the Middle East and African region (*“MEA”*) region, today announces the successful completion of the offering period for retail investors (*“Retail Subscription Period”*) for the Company’s initial public offering (*“IPO”* or the *“Offering”*).

The retail subscription process, comprising of a maximum of 2,100,000 representing 10% of the total Offer Shares, commenced on Tuesday, 30 May 2023 and ended on Thursday, 01 June 2023. It witnessed participation by 170,524 investors, indicating a coverage of 11.0 times, with a total demand of SAR 1.39 billion (USD 0.37 billion). Individual investors will receive a minimum of 4.0 shares each, while the remaining shares will be allocated on a pro-rata basis for the remaining demand with an average allocation factor of 0.5146%.

The final offer price for the Offering has been set at SAR 60 per share (*“Final Offer Price”*), implying a market capitalization of SAR 4.2 billion (USD 1.12 billion) at listing. This follows the successful completion of the book-building process, which resulted in an institutional order book that was over-subscribed by 67.2 times (88.8 times excluding the shares that were allocated to Cornerstone Investors – the Saudi Economic and Development Holding Company (**SEDCO**) and Al Faisaliah Group Holding Company).

Based on the results of the retail subscription period, the shares allocated to Participating Parties will be reduced to 18,900,000 Offer Shares, representing 90% of the total Offering.

Additional details about the Company and the Offering are available in the final prospectus, which is available on the IPO microsite: ipo.jamjoompharma.com/

BACKGROUND TO THE OFFERING

- On 28 December 2022G, the Capital Market Authority (“**CMA**”) approved the Company’s application for the Offering of 21,000,000 shares (the “**Offer Shares**”), representing 30% of the Company’s issued share capital of 70,000,000 shares, by way of a sale of existing Shares by selling shareholders. The final offer price of the Offer Shares has been set at SAR 60 per share following the successful completion of the institutional book-building process.
- With respect to the Offering, the Company appointed Saudi Fransi Capital as Lead Manager (the “**Lead Manager**”) in relation to the Offering. The Company also appointed J.P. Morgan Saudi Arabia Company and Saudi Fransi Capital to act as Financial Advisors (collectively the “**Joint Financial Advisors**”). In addition, the Company also appointed AlRajhi Capital, J.P. Morgan Saudi Arabia Company and Saudi Fransi Capital to act as the Underwriters (the “**Underwriters**”) and as the Bookrunners (the “**Bookrunners**”) to the Offering.
- AlRajhi Bank, Banque Saudi Fransi and Saudi National Bank (SNB) have been appointed as receiving entities (the “**Receiving Entities**”) for the individual investors’ tranche.
- The CMA and Saudi Exchange approvals have been obtained for the offering and listing as outlined below:
 - Jamjoom Pharma to register its shares and offer of twenty-one million (21,000,000) Ordinary Shares representing 30% of the Company’s issued share capital of 70,000,000 shares by way of a sale of existing shares.
 - The Shares will be listed on the Main Market of the Saudi Exchange following the completion of the Offering and listing formalities with the CMA and the Saudi Exchange.
 - All existing shares in Jamjoom Pharma are currently held by members of the Jamjoom family (“**Current Shareholders**”) and each of the Current Shareholders will sell Offer Shares in the IPO pro-rata to their current ownership.
 - The Current Shareholders and the Company will be subject to a lock-up period of six months starting from the commencement of trading of the Shares on the Saudi Stock Exchange.
 - Jamjoom Pharma has entered into a binding undertaking with each of Saudi Economic and Development Holding Company (SEDCO) and Al Faisaliah Group Holding Company (together referred to as the “**Cornerstone Investors**”), through which the Cornerstone Investors have committed to subscribe to, in aggregate, 5,166,666 shares at the Offer Price, representing 24.6% of the Offer Shares and 7.4% of the Company’s issued share capital (“**Cornerstone Commitment**”). The Cornerstone Commitment comprises of 3,499,999 shares to be subscribed by SEDCO and 1,666,667 shares to be subscribed by Al Faisaliah Group Holding Company. The Company agreed to allocate the Cornerstone Investors’ shares to the Cornerstone Investors as part of the Offering process.
 - The Offer Shares will be offered for subscription to investors eligible to participate in the book-building process in accordance with the Book-Building Instructions and Allocation of Shares in IPOs as issued by the CMA (“**Participating Parties**” or “**Participating Party**”), including certain non-US based Qualified Foreign Financial Institutions in accordance with Regulation S under the Securities Act, and individual investors.

- The number of Offer Shares to be initially allocated to the Participating Parties is twenty-one million (21,000,000) Shares representing 100% of the total Offer Shares, of which five million one hundred sixty-six thousand six hundred sixty-six (5,166,666) Offer Shares, being the Cornerstone Investors' Shares, shall be allocated to the Cornerstone Investors.
- A maximum of two million one hundred thousand (2,100,000) shares representing ten percent (10%) of the Offer Shares shall be allocated to Individual Investors. In the event that the Individual Investors do not subscribe in full for the Offer Shares allocated to them, the Lead Manager may reduce the number of Offer Shares allocated to Individual Investors in proportion to the number of Offer Shares subscribed for thereby.
- The Lead Manager shall have the right to reduce the number of Offer Shares allocated to the Participating Parties to a minimum of eighteen million nine-hundred thousand (18,900,000) Shares, representing 90% of the total Offer Shares, provided that such claw-back does not apply to the Cornerstone Investors and the final allocation to the Cornerstone Investors being five million one hundred sixty-six thousand six hundred sixty-six (5,166,666) Offer Shares in all cases.


Expected Offering Timeline

Key Events	Date
Announcement of final Offer Shares allotment	Wednesday 18/11/1444H (corresponding to 07/06/2023G)
Refund of excess subscription amounts (if any)	Sunday 22/11/1444H (corresponding to 11/06/2023G)
Expected date of commencement of trading on the Exchange	It is expected that trading of the Shares will commence on the Exchange shortly after the final allocation of the Offer Shares

Note: The above timelines are indicative. Actual dates will be communicated through announcements appearing on the websites of the Saudi Exchange (www.saudiexchange.com.sa) and the Joint Financial Advisors.

-ENDS-

Company	Email	Role
Jamjoom Pharma	ir@jamjoompharma.com	<ul style="list-style-type: none"> • Issuer
J.P. Morgan Saudi Arabia Company	JP_IPO@jpmorgan.com	<ul style="list-style-type: none"> • Financial Advisor, Bookrunner and Underwriter
Saudi Fransi Capital	Jamjoom.IPO@Fransicapital.com.sa	<ul style="list-style-type: none"> • Lead Manager, Financial Advisor, Bookrunner and Underwriter
AlRajhi Capital	IPO_Jamjoom@alrajhi-capital.sa	<ul style="list-style-type: none"> • Bookrunner and Underwriter
FGS Global	jamjoompharmaipo@fgsglobal.com	<ul style="list-style-type: none"> • Media and Communications Advisor



Disclaimers

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The information in this announcement is subject to change. Neither the Company, nor the Joint Financial Advisors, and their respective affiliates undertake to provide the recipient of this announcement with any additional information, or to update this announcement or to correct any inaccuracies, and the distribution of this announcement shall not be deemed to be any form of commitment on the part of the Company, shareholders, or the Joint Financial Advisors to proceed with the Offering or any transaction or arrangement referred to therein. This announcement has not been approved by any competent regulatory authority. The contents of this announcement are not to be construed as legal, financial, investment or tax advice.

The Offering and the distribution of this announcement and other information in connection with the Offering may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes must inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

This announcement is not an offer for sale of securities of the Company, directly or indirectly, in or into the United States. The Offer Shares may not be offered or sold in the United States unless registered under the US Securities Act of 1933, as amended (the "**Securities Act**"), or offered in a transaction from, or not subject to, the registration requirements of the Securities Act. The Company has not registered and does not intend to register any portion of the Offer Shares under the Securities Act or the laws of any state in the United States or to conduct a public offering of any securities in the United States. Copies of this announcement are not being, and may not be, distributed, forwarded or otherwise sent, directly or indirectly, in or into the United States.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy, the Offer Shares referred to herein to any person in the United States, Australia, Canada, the United Kingdom, South Africa or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The offer and sale of the Offer Shares has not been and will not be registered under the applicable securities laws of Australia, Canada, South Africa or Japan. Subject to certain exceptions, the Offer Shares may not be offered or sold in Australia, Canada, South Africa or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, South Africa or Japan. There will be no public offer of the Offer Shares in the United States, Australia, Canada, South Africa or Japan.

In the European Economic Area (the "**EEA**"), this communication is only addressed to and directed at persons in the member states of the EEA who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended) ("**Qualified Investors**"). In the United Kingdom, this communication is only addressed to and directed at persons who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended), which forms part of the UK law by virtue of the European Union (Withdrawal) Act 2018, who are also: (i) persons having professional experience in matters relating to investments who fall within

the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are other persons to whom it may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being ("**Qualified Investors**")). This communication must not be acted or relied on (i) in the United Kingdom, by persons who are not Relevant Persons and (ii) in any member state of the EEA by persons who are not Qualified Investors. Any investment activity to which this communication relates (i) in the United Kingdom is available only to, and may be engaged in only with, Relevant Persons; and (ii) in any member state of the EEA is available only to, and may be engaged only with, Qualified Investors.

This announcement is being distributed subject to the provisions of the Rules on the Offer of Securities and Continuing Obligations ("**OSCO Rules**") issued by the CMA, and should not result in any binding undertakings to acquire shares or subscribe in the Offering. This announcement is for information purposes only and under no circumstances shall constitute an offer or invitation, or form the basis for a decision, to invest in any securities of the Company. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors may only subscribe in the Offer Shares on the basis of the CMA approved Arabic language prospectus to be issued and published in due course (the "**Local Prospectus**"). The information in this announcement is subject to change. In accordance with Article 51(d) of the OSCO Rules, copies of the Prospectus will, following publication, be available on the websites of the Company at www.jamjoompharma.com, the Saudi Exchange at www.saudiexchange.sa, the CMA at www.cma.org.sa and the Joint Financial Advisors at www.sfc.sa and www.jporgansaudi Arabia.com.

This announcement is not an offer document for the purposes of the OSCO Rules and should not be construed as such. The CMA and the Saudi Exchange do not take any responsibility for the contents of this announcement, do not make any representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this announcement.

The international offering circular prepared in connection with the Offering (the "**International Offering Circular**") is the sole legally binding document containing information about the Company and the Offering outside of Saudi Arabia. In the event of any discrepancy or incompleteness between this announcement and the Local Prospectus and/or the International Offering Circular, as the case may be, the Local Prospectus and/or the International Offering Circular will prevail.

This announcement may include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "aim", "anticipate", "believe", "can", "consider", "could", "estimate", "expect", "forecast", "intend", "may", "ought to", "potential", "plan", "projection", "seek", "should", "will", "would", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. Many factors could cause the actual results to differ materially from those expressed or implied by any such forward-looking statements or contained in projections, including, among other things, risks specifically related to the Company and its operations, the development of global economic and industry conditions, and the impact of economic, political and social developments in Saudi Arabia. Forward-looking statements speak only as of the date they are made. Each of the Company, the Joint Financial Advisors, and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statements contained in this announcement whether as a result of new information, future developments or otherwise.

There is no guarantee that the Offering will occur and you should not base your investment decisions on the Company's intentions in relation to the Offering. This announcement does not constitute a recommendation

concerning the Offering nor any declaration or undertaking by any means. Acquiring Offer Shares to which this announcement relates may expose an investor to a significant risk of losing the entire amount invested. Persons considering investment should consult an investment advisor or an authorized person specializing in advising on such investments.

The Joint Financial Advisors are acting exclusively for the Company and no-one else in connection with the Offering. They will not regard any other person as their respective client, nor for providing advice in relation to the Offering, the contents of this announcement or any transaction, in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, arrangement or other matter referred to herein.

The contents of this announcement have been prepared by and are the sole responsibility of the Company. Neither the Joint Financial Advisors nor any of their respective affiliates, directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

In connection with the Offering, each of the Joint Financial Advisors and any of their affiliates, may take up a portion of the Offer Shares in connection with the Offering as a principal position and in that capacity may retain, purchase, sell, offer to sell for their own accounts such Offer Shares and other securities of the Company or related investments in connection with the Offering or otherwise.

References in the Local Prospectus or the International Offering Circular, once published, to the Company's shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, the Joint Financial Advisors and any of their affiliates acting in such capacity. In addition, the Joint Financial Advisors and any of their affiliates may enter into financing arrangements (including swaps or contracts for difference) with investors in connection with which the Joint Financial Advisors and any of their affiliates may from time to time, acquire, hold or dispose of securities. The Joint Financial Advisors do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.
